Comments
Nectar Lifesciences has received approval from Japan’s Ministry of Health for marketing of ‘Cefuroxime Axetil’ molecules, which are used for treating bacterial infections.
“The Japanese audit is one of the most stringent globally and the fact that we have been approved by the Japanese MOH marks our journey in the regulated path..,” the company CEO and Director, Mr Dinesh Dua, said in a statement.
“Neclife expects business potential for the approved molecule Cefuroxime Axetil to be $10 million,” the company said in a filing to the Bombay Stock Exchange.
The company further said that the pharma market in Japan is set to grow from $68 billion at present to $82 billion in the next few years due to the increasing incentives given by the Government for promoting generic medicines.
Meanwhile, the shares of Nectar Lifesciences were trading at Rs 24.30 in the afternoon trade on the BSE today, up 1.67 per cent from their previous close.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.